MedTrace Logo

Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

NCT00565175 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-03-20

No results posted yet for this study

Summary

The purpose of the study is to investigate whether blockade of the histamine H2 receptors in the brain will have any beneficial effect on the symptoms of subjects with schizophrenia.

Conditions

Interventions

DRUG

famotidine

Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.

DRUG

Placebo (Microcrystallized cellulose)

Placebo administered in identical capsules as the experimental drug.

Sponsors & Collaborators

  • Finland: Lilly saatio foundation

    collaborator UNKNOWN

  • Jesper Ekelund

    lead OTHER

Principal Investigators

  • Jesper Ekelund, MD-PhD · Helsinki University Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565175 on ClinicalTrials.gov